Table 3.

Associations by multivariate logistic regression analyses of gender, IV drug use duration, viral coinfection status, and CCL3L1 copy number with HIV serostatus.

Covariate	Model 1	Model 2	Model 3	Model 4	Model 5
	OR; 95% CI	OR; 95% CI	OR; 95% CI	OR; 95% CI	OR; 95% CI
	P	P	P	P	P
Gender
Male*	1.0	1.0	1.0	1.0	1.0
Female	1.29; 0.687–2.430	1.3; 0.519–3.255	1.297; 0.497–3.389	1.343; 0.706–2.554	1.031; 0.449–2.369
	0.425	0.5751	0.5949	0.3690	0.9424
HCV status
HCV−*	1.0	1.0	1.0	1.0
HCV+	2.08; 1.211–3.572	**	**	2.138; 1.234–3.705
	0.008	0.9459	0.9441	0.0067
HBV status
HBV−*	1.0	1.0	1.0	1.0
HBV+	4.13; 1.943–8.777	0.922; 0.221–3.851	0.657; 0.156–2.772	4.006; 1.875–8.56
	0.0002	0.9115	0.5674	0.0003
IV drug use duration
Yearsa		1.016; 0.944–1.093	1.014; 0.938–1.095		1.08; 1.009–1.157
		0.6665	0.7315		0.0276
CCL3L1 copy number
0–2*			1.0	1.0	1.0
3–6			0.204; 0.093–0.445	0.421; 0.244–0.727	0.267; 0.124–0.574
			<0.0001	0.0019	0.0007

NOTE. Models #1-5 depict multivariate logistic regression analyses with the indicated covariates for the outcome of HIV serostatus. For example, model 1 contains gender and HCV/HBV status whereas model 4 also includes CCL3L1 copy number. Although gender did not associate with HIV serostatus in univariate analyses (Table 2), it was included in the model to remain consistent with the models shown in Table 4.

^*reference group.

^**values reflected those of correlated variables (OR >999.99; 95% CI: <0.001–>999.99). OR, odds ratio; CI, confidence interval; P, significance value.

^aYears was categorized as a continuous variable in full-years, and data reflects an increase in OR with each additional year of IV drug use.